Literature DB >> 17355029

Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report.

Maher Qweider1, Joachim M Gilsbach, Veit Rohde.   

Abstract

Vincristine has a high neurotoxicity level. If given intrathecally by accident, it can cause ascending radiculomyeloencephalopathy, which is almost always fatal. The authors report a rare case in which vincristine was accidentally injected intrathecally into a 32-year-old man. The patient, who had Burkitt lymphoma, was neurologically intact, and it is likely that his survival was made possible due to aggressive neurosurgical therapy. After immediate cerebrospinal fluid (CSF) aspiration, external ventricular and lumbar drains were placed for CSF irrigation, which was continued for 6 days. This CSF irrigation was combined with 1) the intrathecal administration of fresh-frozen plasma to bind the vincristine and 2) an intravenous antineurotoxic therapy involving pyridoxine, folic acid, and glutamic acid. The patient's first sensorimotor deficits occurred after 2 days, led to an incomplete sensorimotor dysfunction below T-9 within the next 17 days, but progressed no further. Supported by the scarce data culled from the reviewed literature, the authors hypothesize that prolonged CSF irrigation combined with antineurotoxic therapy contributed to the patient's satisfactory outcome. In conclusion, accidental intrathecal vincristine injection requires emergency and adequate neurosurgical therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17355029     DOI: 10.3171/spi.2007.6.3.280

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  8 in total

1.  Severe flaccid paraparesis following spinal anaesthesia: a sine materia occurrence.

Authors:  Gentian Vyshka; Giuseppe Vacchiano
Journal:  BMJ Case Rep       Date:  2014-05-15

2.  Clinical Presentation of Inadvertent Intrathecal Vincristine Masquerading Guillain-Barre Syndrome.

Authors:  Agni Sekhar Saha; Md Fekarul Islam; Sukanta Bhattacharya; Prabhas Prasun Giri
Journal:  Indian J Hematol Blood Transfus       Date:  2016-03-12       Impact factor: 0.900

3.  Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers.

Authors:  Annette Nørregaard; Stine Skov Jensen; Jesper Kolenda; Charlotte Aaberg-Jessen; Karina Garnier Christensen; Poul Henning Jensen; Henrik Daa Schrøder; Bjarne Winther Kristensen
Journal:  Neurotox Res       Date:  2011-12-28       Impact factor: 3.911

4.  Efficacy of interstitial continuous vincristine infusion in a bioluminescent rodent intracranial tumor model.

Authors:  Guifa Xi; Barbara Mania-Farnell; Veena Rajaram; Chandra S Mayanil; Marcelo B Soares; Tadanori Tomita; Stewart Goldman
Journal:  J Neurooncol       Date:  2011-08-14       Impact factor: 4.130

Review 5.  Improving the Brain Delivery of Chemotherapeutic Drugs in Childhood Brain Tumors.

Authors:  Silvia Triarico; Palma Maurizi; Stefano Mastrangelo; Giorgio Attinà; Michele Antonio Capozza; Antonio Ruggiero
Journal:  Cancers (Basel)       Date:  2019-06-13       Impact factor: 6.639

6.  Inadvertent intrathecal administration of daunomycin resulting in fatality: Case report and therapeutic considerations.

Authors:  Sauson Soldozy; Anant Patel; Kurt Yaeger; Daniel Felbaum; Steven M Spitz; Hasan R Syed; M Nathan Nair
Journal:  eNeurologicalSci       Date:  2020-11-28

Review 7.  Neuraxial and peripheral misconnection events leading to wrong-route medication errors: a comprehensive literature review.

Authors:  Eugene R Viscusi; Vincent Hugo; Klaus Hoerauf; Frederick S Southwick
Journal:  Reg Anesth Pain Med       Date:  2020-11-03       Impact factor: 6.288

Review 8.  Vincristine-Induced Peripheral Neuropathy in Childhood Acute Lymphoblastic Leukemia: Genetic Variation as a Potential Risk Factor.

Authors:  Qing-Yan Yang; Ya-Hui Hu; Hong-Li Guo; Ying Xia; Yong Zhang; Wei-Rong Fang; Yun-Man Li; Jing Xu; Feng Chen; Yong-Ren Wang; Teng-Fei Wang
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.